Search Results
May 28, 2026, 16:17 ET À la suite d'informations sur les risques de sanctions communiquées par des partenaires occidentaux, le ministère de la justice de la République kirghize suspend 50 entités juridiques dans le cadre du premier recours à une loi interinstitutionnelle visant à réprimer les activités économiques étrangères malveillantes.
rtenaires-occidentaux-le-ministere-de-la-justice-de-la-republique-kirghize-suspend-50-entites-juridiques-dans-le-cadre-du-premier-recours-a-une-loi-int-302784996.html
More news about: The Ministry of Justice of the Kyrgyz Republic
May 28, 2026, 05:00 ET Axi、受賞歴のある資金提供型取引プログラムとManchester Cityとの提携をケープタウンのFMAS:26で披露
せ先： [email protected] ｜詳細はこちら：axi.com/int*Axi Group各社に授与されました。Axi Selectをご利用いただけるのは、AxiTrader LLCの顧客のみです。OTCデリバティブには投資損失の高いリスクがあります。本コンテンツは、地域によってはご利用いただけない場合があります。詳細については、当社の利用規約をご参照ください。通常の取引手数料および最低入金額が適用されます。ロゴ：
More news about: AxiTrader LLC
May 28, 2026, 05:00 ET Axi 在開普敦 FMAS:26 盛會呈獻屢獲殊榮的資金認證交易計劃，並與曼城共創合作佳話
提供涵蓋外匯、股票、黃金、石油、咖啡、加密貨幣等領域的差價合約。媒體查詢：[email protected] | 詳情請見：axi.com/int*授予 Axi 公司集團。 Axi Select 計劃只適用於 AxiTrader LLC 的客戶。 場外 (OTC) 衍生工具涉及高風險，投資可能會招致損失。 此內容或未能在您所在的地區瀏覽。 如欲了解更多資訊，請參閱我們的服務條款。
More news about: AxiTrader LLC
May 28, 2026, 05:00 ET Axi präsentiert sein preisgekröntes Programm für den finanzierten Handel und seine Partnerschaft mit Manchester City auf der FMAS:26 in Kapstadt
[email protected] | Mehr erfahren: axi.com/int*Verliehen an die Axi-Unternehmensgruppe. Das Axi Select-Programm ist nur für Kunden der AxiTrader LLC verfügbar. OTC-Derivate bergen
More news about: AxiTrader LLC
May 28, 2026, 05:00 ET Axi Brings Award-Winning Funded Trading Program and Manchester City Partnership to FMAS:26 in Cape Town
[email protected] | Learn more: axi.com/int*Granted to Axi Group of companies. The Axi Select program is only available to clients of AxiTrader LLC. OTC derivatives carry a high
More news about: AxiTrader LLC
May 28, 2026, 05:00 ET Axi, 상 받은 펀딩 트레이딩 프로그램과 맨체스터 시티 파트너십 앞세워 케이프타운 FMAS:26 참가
[email protected] | 자세한 정보: axi.com/int*Axi 그룹 계열사가 받은 상이다. Axi Select 프로그램은 AxiTrader LLC 고객에게만 제공된다. 장외파생상품(OTC derivatives)은 높은 투자 손실 위험이 있다. 본 콘텐츠는 일부 지역에서는 제공되지 않을 수도 있다.
More news about: AxiTrader LLC
May 28, 2026, 05:00 ET Axi Brings Award-Winning Funded Trading Program and Manchester City Partnership to FMAS:26 in Cape Town
[email protected] | Learn more: axi.com/int*Granted to Axi Group of companies. The Axi Select program is only available to clients of AxiTrader LLC. OTC derivatives carry a high
More news about: AxiTrader LLC
May 28, 2026, 05:00 ET Axi leva programa de trading financiado premiado e parceria com o Manchester City ao FMAS:26 na Cidade do Cabo
[email protected] | Saiba mais: axi.com/int*Concedido ao Grupo de empresas Axi. O programa Axi Select está disponível apenas para clientes da AxiTrader LLC. Derivativos de balcão
More news about: AxiTrader LLC
May 28, 2026, 05:00 ET Axi lleva el galardonado programa de operaciones financiadas y la alianza con el Manchester City a FMAS:26 en Ciudad del Cabo
[email protected] | Más información: axi.com/int*Otorgado a empresas de Axi Group. El programa Axi Select solo está disponible para clientes de AxiTrader LLC. Los derivados bursátiles
More news about: AxiTrader LLC
May 28, 2026, 05:00 ET Axi presenta su galardonado programa de negociación financiada y su alianza con el Manchester City en FMAS:26
[email protected] | Aprenda más en: axi.com/int*Otorgado al grupo de empresas Axi. El programa Axi Select solo está disponible para clientes de AxiTrader LLC. Los derivados OTC conllevan
More news about: AxiTrader LLC
May 28, 2026, 05:00 ET Axi présente au Cap son programme primé de trading financé et son partenariat avec Manchester City, à l'occasion du Sommet 2026 des magnats de la finance en Afrique (FMAS:26)
[email protected] | Pour en savoir plus, veuillez consulter le site axi.com/int*Récompense attribuée au groupe d'entreprises Axi. Le programme Axi Select est uniquement disponible pour les clients d'AxiTrader LLC.
More news about: AxiTrader LLC
May 27, 2026, 07:01 ET ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
2026.Le QA, Greene M, Gohill S, et al. Adherence to multi-target stool DNA testing for colorectal cancer screening in the United States. Int J Colorectal Dis. 2025;40:16.Greene M, Stieber B, LeMaster JW, et al. Closing the loop in colorectal cancer screening: real-world adherence
More news about: Abbott
May 19, 2026, 02:00 ET BIOTRONIK, Charité, and German Heart Center Foundation Announce Partnership to Advance Digital Cardiology
technology."About BIOTRONIK – To find out more, go to https://www.biotronik.com/en-intAbout Charité – Universitätsmedizin Berlin – To find out more, go to
More news about: Biotronik
May 19, 2026, 02:00 ET BIOTRONIK, Charité, and German Heart Center Foundation Announce Partnership to Advance Digital Cardiology
About BIOTRONIK – To find out more, go to https://www.biotronik.com/en-intAbout Charité – Universitätsmedizin Berlin – To find out more, go to
More news about: Biotronik
May 19, 2026, 02:00 ET BIOTRONIK, Charité und Stiftung Deutsches Herzzentrum kooperieren im Bereich digitale Kardiologie
Medizintechnik."Über BIOTRONIK - https://www.biotronik.com/en-intÜber die Charité – Universitätsmedizin Berlin - https://www.charite.de/en/
More news about: Biotronik
May 18, 2026, 08:00 ET Sapient Intelligence launches HRM-Text, challenging the LLM monopoly with a brain-inspired foundation model trained on up to 1000x fewer tokens
The model uses 16 GPUs across two machines, significantly lowering the compute requirements for developing advanced reasoning models.At int4 quantization, HRM-Text occupies approximately 0.6 GiB, making it suitable for on-device and offline deployment within the memory budget of contemporary
More news about: Sapient Intelligence
May 15, 2026, 07:36 ET Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting
PD diagnosis, PD-related symptoms, or a history of seeking treatment for the condition.ReferencesHellstrom WJ. Int J Impot Res. 2003;15(Suppl 5):S91–S92.Stuntz M, Perlaky A, des Vignes F, et al. PLoS One. 2016;11(2):e0150157.DiBenedetti
More news about: Keenova Therapeutics
May 14, 2026, 08:00 ET Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
that are actively reshaping how we deliver patient-centered care.About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
May 11, 2026, 12:27 ET Groundfloor Launches Consumer Credit Portfolio II, Expanding Access to Private Credit Investing
annuallyQuarterly income distributions45-month term structureMinimum investment: $10,000Total offering size: $3 million1099-INT tax reportingGroundfloor's first Consumer Credit Portfolio offering reached full capacity within two weeks and is currently distributing
More news about: Groundfloor Finance Inc.
May 11, 2026, 08:00 ET Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
https://www.nami.org/types-of-conditions/schizophrenia/Alphs L, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable therapy. Int Clin Psychopharmacol. 2016;31(4)202-209. doi:10.1097/YIC.0000000000000125Recourt K, de Boer P, Zuiker R, et al. The selective orexin-2 antagonist
More news about: Johnson & Johnson
May 07, 2026, 16:06 ET Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma.About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.
More news about: Intensity Therapeutics Inc.
May 06, 2026, 00:00 ET Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia
Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59.[2]
More news about: Alebund Pharmaceuticals
May 05, 2026, 18:16 ET Multi-Stakeholder Expert Panel Finds UTI Management in the United States Represents a Solvable Systemic Failure Costing More Than $6 Billion Annually
L.K.S.; Wang, D.; Stapleton, A.E.; Lukacz, E.S. Microbial Threshold Guidelines for UTI Diagnosis: A Scoping Systematic Review. Pathol. Lab. Med. Int. 2023, 15, 43–63, doi:10.2147/PLMI.S409488.5 Festa, R.A.; Luke, N.; Mathur, M.; Parnell, L.; Wang, D.; Zhao, X.; Magallon, J.;
More news about: Pathnostics
May 05, 2026, 17:01 ET Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
https://mhraproducts4853.blob.core.windows.net/docs/07df769800514385e1a35a9bacc554d590f6cf1b Accessed April 2026Meijer AJM, et al. Front Oncol 2024; 14: 1336714Tan WJT, Vlajkovic SM. Int J Mol Sci 2023; 24(22): 16545PEDMARQSI® Consumer Medicines Information (CMI):
More news about: Norgine
May 05, 2026, 17:01 ET Norgine begrüßt die TGA-Zulassung von PEDMARQSI® (Natriumthiosulfat wasserfrei) in Australien zur Vorbeugung von Cisplatin-induziertem Hörverlust bei Kindern1
https://mhraproducts4853.blob.core.windows.net/docs/07df769800514385e1a35a9bacc554d590f6cf1b Accessed April 2026Meijer AJM, et al. Front Oncol 2024; 14: 1336714Tan WJT, Vlajkovic SM. Int J Mol Sci 2023; 24(22): 16545PEDMARQSI® Arzneimittelinformationen für Verbraucher (CMI):
More news about: Norgine